Oral versus intravenous iron for anemia in pregnancy: a cost-effectiveness analysis

Authors

Wayde D. Dazelle
Megan K. Ebner, The George Washington University School of Medicine and Health Sciences, Washington, United States.
Savita Potarazu, The George Washington University School of Medicine and Health Sciences, Washington, United States.
Jamil Kazma, George Washington University Hosptial, Washington DC, United States.
Homa Ahmadzia, OB/Gyn, George Washington University Medical Faculty Associates, Washington, United States.

Document Type

Journal Article

Publication Date

1-30-2024

Journal

American journal of perinatology

DOI

10.1055/a-2257-3586

Abstract

Our findings suggest that treating antepartum anemia with currently available iron therapies would result in significant cost-savings and reductions in adverse outcomes associated with anemia in this context. Ferric carboxymaltose likely confers the greatest overall benefit among competing options. This conclusion is robust to uncertainty, even when the cost these therapies is significantly higher than is demonstrated in the literature.

APA Citation

Dazelle, Wayde D.; Ebner, Megan K.; Potarazu, Savita; Kazma, Jamil; and Ahmadzia, Homa, "Oral versus intravenous iron for anemia in pregnancy: a cost-effectiveness analysis" (2024). GW Authored Works. Paper 4106.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/4106

Department

Obstetrics and Gynecology